Hester Biosciences Limited has informed the Exchange regarding Outcome of Board Meeting held on March 11, 2026.
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.3 pts less than Nifty Microcap 250 and 2.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hester Biosciences' board approved selling its 43.81% stake (out of 54.81%) in subsidiary Texas Lifesciences Private Limited (TLPL) to Ticop Life Private Limited, a company linked to TLPL's existing promoters, for a total consideration of INR 92 million. After the sale, Hester will retain an 11% stake and TLPL will cease to be its subsidiary. The agreement was signed on March 5, 2026, and the share transfer is to be completed within three months. TLPL is classified as a non-material subsidiary, with FY25 turnover of INR 285.89 million and net worth of INR 134.17 million, though over 97% of its sales were to Hester itself and thus eliminated in consolidated accounts.
This is a non-material subsidiary cleanup with negligible impact on consolidated revenue or earnings, as nearly all of TLPL's sales were intercompany. The INR 92 million inflow is small relative to Hester's overall size, so the stock is unlikely to see a meaningful price reaction, though it streamlines the group structure.